Research Priority Areas
The Dana-Farber pLGG Program brings together 10 multidisciplinary laboratories dedicated to studying pLGGs and related brain tumors —creating opportunities for synergistic therapeutic advances across tumor subtypes. Our researchers have mapped key mutations in pediatric gliomas and have identified novel therapeutic agents, including the recently FDA-approved Tovorafenib. Our overall research priorities are outlined below.
1. Determine the cause and drivers of pLGG
Using state-of-the-art genomics and high-throughput analytical techniques, we seek to discover the fundamental drivers of pLGG development, revealing powerful therapeutic targets diagnostic strategies and therapeutic targets.
2. Develop high-throughput methods to study pLGG in a laboratory setting
We develop powerful laboratory models for high-throughput investigation within a laboratory setting. By reproducing these unique tumors, we can better understand how these tumors form, and importantly, can test novel therapeutics for safety and efficacy.
3. Develop effective and safe therapeutics for every pLGG patient
Through next-generation genomics, imaging, chemistry, and artificial intelligence, we seek to develop safer and effective treatments for every pLGG patient.
4. Pursue strategies to maximize survivorship and quality of life
We pursue strategies to maximize survivorship without toxicities from tumors and their treatments.
